{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T21:56:07Z","timestamp":1788386167667,"version":"build-2803163510"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2022,5,16]],"date-time":"2022-05-16T00:00:00Z","timestamp":1652659200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,5,16]],"date-time":"2022-05-16T00:00:00Z","timestamp":1652659200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Familial Cancer"],"published-print":{"date-parts":[[2022,10]]},"DOI":"10.1007\/s10689-022-00292-2","type":"journal-article","created":{"date-parts":[[2022,5,16]],"date-time":"2022-05-16T03:24:11Z","timestamp":1652671451000},"page":"463-472","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Long-term chemoprevention in patients with adenomatous polyposis coli: an observational study"],"prefix":"10.1007","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7731-7335","authenticated-orcid":false,"given":"Teresa M.","family":"Neuhann","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katharina","family":"Haub","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8491-3234","authenticated-orcid":false,"given":"Verena","family":"Steinke-Lange","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0809-8404","authenticated-orcid":false,"given":"Monika","family":"Morak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4596-7293","authenticated-orcid":false,"given":"Andreas","family":"Laner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melanie","family":"Locher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elke","family":"Holinski-Feder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,5,16]]},"reference":[{"key":"292_CR1","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1056\/NEJMoa061355","volume":"355","author":"MM Bertagnolli","year":"2006","unstructured":"Bertagnolli MM, Eagle CJ, Zauber AG et al (2006) Celecoxib for the prevention of sporadic colorectal adenomas. N Engl J Med 355:873\u2013884. https:\/\/doi.org\/10.1056\/NEJMoa061355","journal-title":"N Engl J Med"},{"key":"292_CR2","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1053\/gast.2002.31890","volume":"122","author":"M Cruz-Correa","year":"2002","unstructured":"Cruz-Correa M, Hylind LM, Romans KE et al (2002) Long-term treatment with sulindac in familial adenomatous polyposis: a prospective cohort study. Gastroenterology 122:641\u2013645","journal-title":"Gastroenterology"},{"key":"292_CR3","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1056\/NEJMoa012015","volume":"346","author":"FM Giardiello","year":"2002","unstructured":"Giardiello FM, Yang VW, Hylind LM et al (2002) Primary chemoprevention of familial adenomatous polyposis with sulindac. N Engl J Med 346:1054\u20131059. https:\/\/doi.org\/10.1056\/NEJMoa012015","journal-title":"N Engl J Med"},{"key":"292_CR4","doi-asserted-by":"publisher","first-page":"1618","DOI":"10.1002\/bjs.1800801244","volume":"80","author":"KP Nugent","year":"1993","unstructured":"Nugent KP, Farmer KC, Spigelman AD et al (1993) Randomized controlled trial of the effect of sulindac on duodenal and rectal polyposis and cell proliferation in patients with familial adenomatous polyposis. Br J Surg 80:1618\u20131619","journal-title":"Br J Surg"},{"key":"292_CR5","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.1016\/0016-5085(94)90246-1","volume":"107","author":"CE Eberhart","year":"1994","unstructured":"Eberhart CE, Coffey RJ, Radhika A et al (1994) Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas. Gastroenterology 107:1183\u20131188. https:\/\/doi.org\/10.1016\/0016-5085(94)90246-1","journal-title":"Gastroenterology"},{"key":"292_CR6","first-page":"2556","volume":"55","author":"SL Kargman","year":"1995","unstructured":"Kargman SL, O\u2019Neill GP, Vickers PJ et al (1995) Expression of prostaglandin G\/H synthase-1 and -2 protein in human colon cancer. Cancer Res 55:2556\u20132559","journal-title":"Cancer Res"},{"key":"292_CR7","doi-asserted-by":"publisher","DOI":"10.1007\/s10689-020-00189-y","author":"PM Kemp Bohan","year":"2020","unstructured":"Kemp Bohan PM, Mankaney G, Vreeland TJ et al (2020) Chemoprevention in familial adenomatous polyposis: past, present and future. Fam Cancer. https:\/\/doi.org\/10.1007\/s10689-020-00189-y","journal-title":"Fam Cancer"},{"key":"292_CR8","doi-asserted-by":"publisher","first-page":"1946","DOI":"10.1056\/NEJM200006293422603","volume":"342","author":"G Steinbach","year":"2000","unstructured":"Steinbach G, Lynch PM, Phillips RK et al (2000) The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N Engl J Med 342:1946\u20131952. https:\/\/doi.org\/10.1056\/NEJM200006293422603","journal-title":"N Engl J Med"},{"key":"292_CR9","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1136\/gut.50.6.857","volume":"50","author":"RKS Phillips","year":"2002","unstructured":"Phillips RKS, Wallace MH, Lynch PM et al (2002) A randomised, double blind, placebo controlled study of celecoxib, a selective cyclooxygenase 2 inhibitor, on duodenal polyposis in familial adenomatous polyposis. Gut 50:857\u2013860. https:\/\/doi.org\/10.1136\/gut.50.6.857","journal-title":"Gut"},{"key":"292_CR10","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.1056\/NEJMoa050493","volume":"352","author":"RS Bresalier","year":"2005","unstructured":"Bresalier RS, Sandler RS, Quan H et al (2005) Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med 352:1092\u20131102. https:\/\/doi.org\/10.1056\/NEJMoa050493","journal-title":"N Engl J Med"},{"key":"292_CR11","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1056\/NEJMoa050405","volume":"352","author":"SD Solomon","year":"2005","unstructured":"Solomon SD, McMurray JJV, Pfeffer MA et al (2005) Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med 352:1071\u20131080. https:\/\/doi.org\/10.1056\/NEJMoa050405","journal-title":"N Engl J Med"},{"key":"292_CR12","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1158\/1940-6207.CAPR-11-0106","volume":"4","author":"J Burn","year":"2011","unstructured":"Burn J, Bishop DT, Chapman PD et al (2011) A randomized placebo-controlled prevention trial of aspirin and\/or resistant starch in young people with familial adenomatous polyposis. Cancer Prev Res (Phila) 4:655\u2013665. https:\/\/doi.org\/10.1158\/1940-6207.CAPR-11-0106","journal-title":"Cancer Prev Res (Phila)"},{"key":"292_CR13","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1158\/1940-6207.CAPR-08-0042","volume":"1","author":"FL Meyskens","year":"2008","unstructured":"Meyskens FL, McLaren CE, Pelot D et al (2008) Difluoromethylornithine plus sulindac for the prevention of sporadic colorectal adenomas: a randomized placebo-controlled, double-blind trial. Cancer Prev Res (Phila) 1:32\u201338. https:\/\/doi.org\/10.1158\/1940-6207.CAPR-08-0042","journal-title":"Cancer Prev Res (Phila)"},{"key":"292_CR14","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2014-307235","author":"PM Lynch","year":"2015","unstructured":"Lynch PM, Burke CA, Phillips R et al (2015) An international randomised trial of celecoxib versus celecoxib plus difluoromethylornithine in patients with familial adenomatous polyposis. Gut. https:\/\/doi.org\/10.1136\/gutjnl-2014-307235","journal-title":"Gut"},{"key":"292_CR15","doi-asserted-by":"publisher","first-page":"1266","DOI":"10.1001\/jama.2016.2522","volume":"315","author":"NJ Samadder","year":"2016","unstructured":"Samadder NJ, Neklason DW, Boucher KM et al (2016) Effect of sulindac and erlotinib vs placebo on duodenal neoplasia in familial adenomatous polyposis: a randomized clinical trial. JAMA 315:1266. https:\/\/doi.org\/10.1001\/jama.2016.2522","journal-title":"JAMA"},{"key":"292_CR16","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2017.5431","author":"NJ Samadder","year":"2018","unstructured":"Samadder NJ, Kuwada SK, Boucher KM et al (2018) Association of sulindac and erlotinib vs placebo with colorectal neoplasia in familial adenomatous polyposis: secondary analysis of a randomized clinical trial. JAMA Oncol. https:\/\/doi.org\/10.1001\/jamaoncol.2017.5431","journal-title":"JAMA Oncol"},{"key":"292_CR17","doi-asserted-by":"publisher","first-page":"1028","DOI":"10.1056\/NEJMoa1916063","volume":"383","author":"CA Burke","year":"2020","unstructured":"Burke CA, Dekker E, Lynch P et al (2020) Eflornithine plus sulindac for prevention of progression in familial adenomatous polyposis. N Engl J Med 383:1028\u20131039. https:\/\/doi.org\/10.1056\/NEJMoa1916063","journal-title":"N Engl J Med"},{"key":"292_CR18","doi-asserted-by":"publisher","DOI":"10.1186\/s12876-016-0494-4","author":"CA Burke","year":"2016","unstructured":"Burke CA, Dekker E, Samadder NJ et al (2016) Efficacy and safety of eflornithine (CPP-1X)\/sulindac combination therapy versus each as monotherapy in patients with familial adenomatous polyposis (FAP): design and rationale of a randomized, double-blind, Phase III trial. BMC Gastroenterol. https:\/\/doi.org\/10.1186\/s12876-016-0494-4","journal-title":"BMC Gastroenterol"},{"key":"292_CR19","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1136\/gut.2009.200642","volume":"59","author":"NJ West","year":"2010","unstructured":"West NJ, Clark SK, Phillips RKS et al (2010) Eicosapentaenoic acid reduces rectal polyp number and size in familial adenomatous polyposis. Gut 59:918\u2013925. https:\/\/doi.org\/10.1136\/gut.2009.200642","journal-title":"Gut"},{"key":"292_CR20","doi-asserted-by":"publisher","first-page":"1434","DOI":"10.1002\/1097-0142(19821001)50:7<1434::aid-cncr2820500733>3.0.co;2-f","volume":"50","author":"HJ Bussey","year":"1982","unstructured":"Bussey HJ, DeCosse JJ, Deschner EE et al (1982) A randomized trial of ascorbic acid in polyposis coli. Cancer 50:1434\u20131439. https:\/\/doi.org\/10.1002\/1097-0142(19821001)50:7%3c1434::aid-cncr2820500733%3e3.0.co;2-f","journal-title":"Cancer"},{"key":"292_CR21","doi-asserted-by":"publisher","first-page":"1040","DOI":"10.1038\/ajg.2016.159","volume":"111","author":"H Yuksekkaya","year":"2016","unstructured":"Yuksekkaya H, Yucel A, Gumus M et al (2016) Familial adenomatous polyposis; succesful use of sirolimus. Am J Gastroenterol 111:1040\u20131041. https:\/\/doi.org\/10.1038\/ajg.2016.159","journal-title":"Am J Gastroenterol"},{"key":"292_CR22","doi-asserted-by":"publisher","first-page":"16620","DOI":"10.3748\/wjg.v20.i44.16620","volume":"20","author":"FG Campos","year":"2014","unstructured":"Campos FG (2014) Surgical treatment of familial adenomatous polyposis: dilemmas and current recommendations. World J Gastroenterol 20:16620\u201316629. https:\/\/doi.org\/10.3748\/wjg.v20.i44.16620","journal-title":"World J Gastroenterol"},{"key":"292_CR23","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/j.celrep.2017.09.020","volume":"21","author":"S Ag\u00fcera-Gonz\u00e1lez","year":"2017","unstructured":"Ag\u00fcera-Gonz\u00e1lez S, Burton OT, V\u00e1zquez-Ch\u00e1vez E et al (2017) Adenomatous polyposis coli defines treg differentiation and anti-inflammatory function through microtubule-mediated NFAT localization. Cell Rep 21:181\u2013194. https:\/\/doi.org\/10.1016\/j.celrep.2017.09.020","journal-title":"Cell Rep"},{"key":"292_CR24","doi-asserted-by":"publisher","first-page":"5490","DOI":"10.1158\/0008-5472.CAN-09-0304","volume":"69","author":"E Gounaris","year":"2009","unstructured":"Gounaris E, Blatner NR, Dennis K et al (2009) T-regulatory cells shift from a protective anti-inflammatory to a cancer-promoting proinflammatory phenotype in polyposis. Cancer Res 69:5490\u20135497. https:\/\/doi.org\/10.1158\/0008-5472.CAN-09-0304","journal-title":"Cancer Res"},{"key":"292_CR25","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1016\/j.gie.2016.08.005","volume":"85","author":"LS Cassani","year":"2017","unstructured":"Cassani LS, Lanke G, Chen H-C et al (2017) Comparison of nonampullary duodenal adenomas in patients with familial adenomatous polyposis versus patients with sporadic adenomas. Gastrointest Endosc 85:803\u2013812. https:\/\/doi.org\/10.1016\/j.gie.2016.08.005","journal-title":"Gastrointest Endosc"},{"key":"292_CR26","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.critrevonc.2006.07.004","volume":"61","author":"MH Nieuwenhuis","year":"2007","unstructured":"Nieuwenhuis MH, Vasen HFA (2007) Correlations between mutation site in APC and phenotype of familial adenomatous polyposis (FAP): a review of the literature. Crit Rev Oncol Hematol 61:153\u2013161. https:\/\/doi.org\/10.1016\/j.critrevonc.2006.07.004","journal-title":"Crit Rev Oncol Hematol"},{"key":"292_CR27","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1016\/0959-8049(95)00137-8","volume":"31A","author":"FM Giardiello","year":"1995","unstructured":"Giardiello FM, Offerhaus GJ, DuBois RN (1995) The role of nonsteroidal anti-inflammatory drugs in colorectal cancer prevention. Eur J Cancer 31A:1071\u20131076. https:\/\/doi.org\/10.1016\/0959-8049(95)00137-8","journal-title":"Eur J Cancer"},{"key":"292_CR28","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1016\/s0140-6736(94)91253-x","volume":"343","author":"D Labayle","year":"1994","unstructured":"Labayle D, Boyer J, Drouhin F et al (1994) Sulindac in familial adenomatous polyposis. Lancet 343:417\u2013418. https:\/\/doi.org\/10.1016\/s0140-6736(94)91253-x","journal-title":"Lancet"},{"key":"292_CR29","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.1038\/ajg.2009.758","volume":"105","author":"PM Lynch","year":"2010","unstructured":"Lynch PM, Ayers GD, Hawk E et al (2010) The safety and efficacy of celecoxib in children with familial adenomatous polyposis. Am J Gastroenterol 105:1437\u20131443. https:\/\/doi.org\/10.1038\/ajg.2009.758","journal-title":"Am J Gastroenterol"},{"key":"292_CR30","first-page":"4756","volume":"9","author":"T Higuchi","year":"2003","unstructured":"Higuchi T, Iwama T, Yoshinaga K et al (2003) A randomized, double-blind, placebo-controlled trial of the effects of rofecoxib, a selective cyclooxygenase-2 inhibitor, on rectal polyps in familial adenomatous polyposis patients. Clin Cancer Res 9:4756\u20134760","journal-title":"Clin Cancer Res"},{"key":"292_CR31","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1007\/s10147-005-0548-z","volume":"11","author":"T Iwama","year":"2006","unstructured":"Iwama T, Akasu T, Utsunomiya J, Muto T (2006) Does a selective cyclooxygenase-2 inhibitor (tiracoxib) induce clinically sufficient suppression of adenomas in patients with familial adenomatous polyposis? A randomized double-blind placebo-controlled clinical trial. Int J Clin Oncol 11:133\u2013139. https:\/\/doi.org\/10.1007\/s10147-005-0548-z","journal-title":"Int J Clin Oncol"},{"key":"292_CR32","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1016\/0002-9610(89)90442-X","volume":"157","author":"WR Waddell","year":"1989","unstructured":"Waddell WR, Ganser GF, Cerise EJ, Loughry RW (1989) Sulindac for polyposis of the colon. Am J Surg 157:175\u2013179","journal-title":"Am J Surg"},{"key":"292_CR33","doi-asserted-by":"publisher","first-page":"952","DOI":"10.7326\/0003-4819-115-12-952","volume":"115","author":"J Rigau","year":"1991","unstructured":"Rigau J, Piqu\u00e9 JM, Rubio E et al (1991) Effects of long-term sulindac therapy on colonic polyposis. Ann Intern Med 115:952\u2013954. https:\/\/doi.org\/10.7326\/0003-4819-115-12-952","journal-title":"Ann Intern Med"},{"key":"292_CR34","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1016\/0016-5085(94)90593-2","volume":"106","author":"MT Spagnesi","year":"1994","unstructured":"Spagnesi MT, Tonelli F, Dolara P et al (1994) Rectal proliferation and polyp occurrence in patients with familial adenomatous polyposis after sulindac treatment. Gastroenterology 106:362\u2013366. https:\/\/doi.org\/10.1016\/0016-5085(94)90593-2","journal-title":"Gastroenterology"},{"key":"292_CR35","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1007\/s10147-004-0417-1","volume":"9","author":"H Ishikawa","year":"2004","unstructured":"Ishikawa H (2004) Chemoprevention of carcinogenesis in familial tumors. Int J Clin Oncol 9:299\u2013303. https:\/\/doi.org\/10.1007\/s10147-004-0417-1","journal-title":"Int J Clin Oncol"},{"key":"292_CR36","doi-asserted-by":"publisher","first-page":"1156","DOI":"10.1007\/bf02055161","volume":"40","author":"G Winde","year":"1997","unstructured":"Winde G, Schmid KW, Brandt B et al (1997) Clinical and genomic influence of sulindac on rectal mucosa in familial adenomatous polyposis. Dis Colon Rectum 40:1156\u20131168. https:\/\/doi.org\/10.1007\/bf02055161 (discussion 1168\u20131169)","journal-title":"Dis Colon Rectum"},{"key":"292_CR37","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1002\/1096-9098(200005)74:1<15::aid-jso4>3.0.co;2-z","volume":"74","author":"F Tonelli","year":"2000","unstructured":"Tonelli F, Valanzano R, Messerini L, Ficari F (2000) Long-term treatment with sulindac in familial adenomatous polyposis: is there an actual efficacy in prevention of rectal cancer? J Surg Oncol 74:15\u201320. https:\/\/doi.org\/10.1002\/1096-9098(200005)74:1%3c15::aid-jso4%3e3.0.co;2-z","journal-title":"J Surg Oncol"},{"key":"292_CR38","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1080\/110241501750215285","volume":"167","author":"F Fern\u00e1ndez-L\u00f3pez","year":"2001","unstructured":"Fern\u00e1ndez-L\u00f3pez F, Conde-Freire R, Cadarso-Su\u00e1rez C et al (2001) Sulindac in familial adenomatous polyposis: evaluation by nuclear morphometry. Eur J Surg 167:375\u2013381. https:\/\/doi.org\/10.1080\/110241501750215285","journal-title":"Eur J Surg"},{"key":"292_CR39","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.1007\/bf02234627","volume":"44","author":"I Guldenschuh","year":"2001","unstructured":"Guldenschuh I, Hurlimann R, Muller A et al (2001) Relationship between APC genotype, polyp distribution, and oral sulindac treatment in the colon and rectum of patients with familial adenomatous polyposis. Dis Colon Rectum 44:1090\u20131097. https:\/\/doi.org\/10.1007\/bf02234627 (discussion 1097\u20131099)","journal-title":"Dis Colon Rectum"},{"key":"292_CR40","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1111\/j.1440-1746.2006.04181.x","volume":"21","author":"T Matsumoto","year":"2006","unstructured":"Matsumoto T, Nakamura S, Esaki M et al (2006) Effect of the non-steroidal anti-inflammatory drug sulindac on colorectal adenomas of uncolectomized familial adenomatous polyposis. J Gastroenterol Hepatol 21:251\u2013257. https:\/\/doi.org\/10.1111\/j.1440-1746.2006.04181.x","journal-title":"J Gastroenterol Hepatol"},{"key":"292_CR41","first-page":"1259","volume":"49","author":"T Akasu","year":"2002","unstructured":"Akasu T, Yokoyama T, Sugihara K et al (2002) Peroral sustained-release indomethacin treatment for rectal adenomas in familial adenomatous polyposis: a pilot study. Hepatogastroenterology 49:1259\u20131261","journal-title":"Hepatogastroenterology"},{"key":"292_CR42","doi-asserted-by":"publisher","first-page":"1660","DOI":"10.1002\/(SICI)1097-0142(19961015)78:8<1660::AID-CNCR4>3.0.CO;2-I","volume":"78","author":"C Hirota","year":"1996","unstructured":"Hirota C, Iida M, Aoyagi K et al (1996) Effect of indomethacin suppositories on rectal polyposis in patients with familial adenomatous polyposis. Cancer 78:1660\u20131665","journal-title":"Cancer"},{"key":"292_CR43","doi-asserted-by":"publisher","first-page":"1168","DOI":"10.1080\/003655299750025002","volume":"34","author":"P Dolara","year":"1999","unstructured":"Dolara P, Caderni G, Tonelli F (1999) Nimesulide, a selective anti-inflammatory cyclooxygenase-2 inhibitor, does not affect polyp number and mucosal proliferation in familial adenomatous polyposis. Scand J Gastroenterol 34:1168. https:\/\/doi.org\/10.1080\/003655299750025002","journal-title":"Scand J Gastroenterol"},{"key":"292_CR44","first-page":"78","volume":"6","author":"R van Stolk","year":"2000","unstructured":"van Stolk R, Stoner G, Hayton WL et al (2000) Phase I trial of exisulind (sulindac sulfone, FGN-1) as a chemopreventive agent in patients with familial adenomatous polyposis. Clin Cancer Res 6:78\u201389","journal-title":"Clin Cancer Res"},{"key":"292_CR45","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1016\/j.bpg.2011.08.002","volume":"25","author":"B Kim","year":"2011","unstructured":"Kim B, Giardiello FM (2011) Chemoprevention in familial adenomatous polyposis. Best Pract Res Clin Gastroenterol 25:607\u2013622. https:\/\/doi.org\/10.1016\/j.bpg.2011.08.002","journal-title":"Best Pract Res Clin Gastroenterol"},{"key":"292_CR46","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1056\/NEJM199305063281805","volume":"328","author":"FM Giardiello","year":"1993","unstructured":"Giardiello FM, Hamilton SR, Krush AJ et al (1993) Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis. N Engl J Med 328:1313\u20131316. https:\/\/doi.org\/10.1056\/NEJM199305063281805","journal-title":"N Engl J Med"},{"key":"292_CR47","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1023\/A:1018898120673","volume":"43","author":"FM Giardiello","year":"1998","unstructured":"Giardiello FM, Spannhake EW, DuBois RN et al (1998) Prostaglandin levels in human colorectal mucosa: effects of sulindac in patients with familial adenomatous polyposis. Dig Dis Sci 43:311\u2013316","journal-title":"Dig Dis Sci"},{"key":"292_CR48","doi-asserted-by":"publisher","first-page":"854","DOI":"10.1016\/0016-5085(94)90136-8","volume":"107","author":"Y Niv","year":"1994","unstructured":"Niv Y, Fraser GM (1994) Adenocarcinoma in the rectal segment in familial polyposis coli is not prevented by sulindac therapy. Gastroenterology 107:854\u2013857. https:\/\/doi.org\/10.1016\/0016-5085(94)90136-8","journal-title":"Gastroenterology"},{"key":"292_CR49","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1002\/1097-0142(19950215)75:4<936::aid-cncr2820750407>3.0.co;2-q","volume":"75","author":"HT Lynch","year":"1995","unstructured":"Lynch HT, Thorson AG, Smyrk T (1995) Rectal cancer after prolonged sulindac chemoprevention. A case report. Cancer 75:936\u2013938. https:\/\/doi.org\/10.1002\/1097-0142(19950215)75:4%3c936::aid-cncr2820750407%3e3.0.co;2-q","journal-title":"Cancer"},{"key":"292_CR50","doi-asserted-by":"publisher","first-page":"1381","DOI":"10.1093\/jnci\/89.18.1381","volume":"89","author":"H Ishikawa","year":"1997","unstructured":"Ishikawa H, Akedo I, Suzuki T et al (1997) Adverse effects of sulindac used for prevention of colorectal cancer. J Natl Cancer Inst 89:1381. https:\/\/doi.org\/10.1093\/jnci\/89.18.1381","journal-title":"J Natl Cancer Inst"},{"key":"292_CR51","doi-asserted-by":"publisher","first-page":"2104","DOI":"10.1161\/CIRCULATIONAHA.108.764530","volume":"117","author":"SD Solomon","year":"2008","unstructured":"Solomon SD, Wittes J, Finn PV et al (2008) Cardiovascular risk of celecoxib in 6 randomized placebo-controlled trials: the cross trial safety analysis. Circulation 117:2104\u20132113. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.108.764530","journal-title":"Circulation"}],"container-title":["Familial Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10689-022-00292-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10689-022-00292-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10689-022-00292-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,4]],"date-time":"2022-11-04T10:55:14Z","timestamp":1667559314000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10689-022-00292-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,16]]},"references-count":51,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,10]]}},"alternative-id":["292"],"URL":"https:\/\/doi.org\/10.1007\/s10689-022-00292-2","relation":{},"ISSN":["1389-9600","1573-7292"],"issn-type":[{"value":"1389-9600","type":"print"},{"value":"1573-7292","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,16]]},"assertion":[{"value":"12 April 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 March 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 May 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All authors declare that they have no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Yes, project no. 19-005, ethics committee of the Ludwig Maximilian University Munich, Germany (28.05.2019).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}